{"id":2949,"date":"2016-10-04T12:35:10","date_gmt":"2016-10-04T10:35:10","guid":{"rendered":"https:\/\/www.farmaindustria.es\/web_en\/?p=2949"},"modified":"2016-10-04T12:37:26","modified_gmt":"2016-10-04T10:37:26","slug":"innovation-product-type-industrial-protection-keys-success-farma-biotechs-programme","status":"publish","type":"post","link":"https:\/\/www.farmaindustria.es\/web_en\/documents\/press-releases\/2016\/10\/04\/innovation-product-type-industrial-protection-keys-success-farma-biotechs-programme\/","title":{"rendered":"Innovation, product type and industrial protection \u2013 the keys to the success of Farma-Biotech\u2019s programme"},"content":{"rendered":"<p style=\"text-align: justify\"><strong>Bilbao, September 30th 2016<\/strong>.- Small biotech companies and start-ups, R&amp;D centers and pharmaceutical companies have highlighted the benefits that the Farma-Biotech program has generated for their activities. The Program was set up five years ago by <a href=\"https:\/\/www.farmaindustria.es\/web\/\">Farmaindustria<\/a>, and a summary of its recent activities was presented today in Bilbao in the context of the Biospain fair.<\/p>\n<p style=\"text-align: justify\">The initiative, which fosters the cooperation of the pharmaceutical industry with small biotechnology companies, universities, hospitals and R&amp;D centers, largely bases its success on its projects selection criteria: therapeutic area of innovation, product type, innovative action mechanism, degree of differentiation to other developments or products, phase of advance in the development of medicine and status of industrial protection.<\/p>\n<p style=\"text-align: justify\">Farmaindustria\u2019s Innovative Medicines Platform Manager, Amelia Mart\u00edn Uranga, remarked during the gathering that, Farma-Biotech \u201cis an original program, with a good selection process and an adequate format; it is also necessary, since it contributes to the development of the pharmaceutical innovation ecosystem, and it is forever focusing on a continued improvement process with the aim of increasing public-private collaboration and raise the international visibility of Spanish capacities in this field\u201d.<\/p>\n<p style=\"text-align: justify\">Farma-Biotech\u2019s operation mechanism is simple. Farmaindustria\u2019s working team searches, receives and analyzes numerous in-development projects each year, coming both from Spanish small biotechnological companies, as well as from research centers and private and public hospitals. Between 2011 and 2015, 14 cooperation working days were called for, gathering together companies and promoters, in which 102 selected projects were presented amongst 412 received proposals.<\/p>\n<p style=\"text-align: justify\"><strong>Five projects already available on the market<\/strong><\/p>\n<p style=\"text-align: justify\">From the 102 presented projects celebrated in different sessions, 63 of them still remain active. From them, 12 are already in clinical trials and five are available on the market. The next working day, which will mark its fifteenth edition, will be held in Madrid on November 15th, and 8 new projects of advanced research will be presented, amongst 54 proposals received during the first semester of 2016.<\/p>\n<p style=\"text-align: justify\">Mar\u00eda Aguirre, Research and Innovation Director of the Basque Country\u2019s Government, remarked during her speech in Bilbao the importance of these kinds of programmes to facilitate public-private collaboration in the field of biomedical R&amp;D. Amongst the objectives of the Euskadi\u2019s 2020 Strategy in Health Research and\u00a0Innovation, we find it important the \u201cincreasing the collaboration with companies and technological and scientific agents, in order to turn the system into a partner of choice\u201d, as well as \u201cfostering the development of innovations, with the healthcare system as a traction element\u201d.<\/p>\n<p style=\"text-align: justify\">Javier Garc\u00eda Cogorro, CEO of the company Bioncotech, described the aspects regarding the development of products which are more important to a biotech Enterprise: the engagement with regulators, the role of investors and elements related to business development which should be planned from the beginning. On the other hand, he informed that Bioncotech has already recruited its first patient for the clinical trial of their first medicine.<\/p>\n<p style=\"text-align: justify\">Anabel Sanz, Transfer Technology Director at the Spanish National Oncologic Research Center (CNIO), explained the experience of this institution with regards to Farma-Biotech, in which they participate from the early editions, and remarked her interest in the collaboration strategy with the Severo Ochoa centers of excellence recently set up by Farmaindustria.<\/p>\n<p style=\"text-align: justify\">From the pharmaceutical industry\u2019s side, Andr\u00e9s G. Fern\u00e1ndez, Director of Ferrer Advanced Biotherapeutics, concluded that Farma-Biotech is particularly useful to Spanish companies because of the proximity of decision centers, the day to day relation with key people involved in the decision making process, the maturity of the projects as well as their simple monitoring and plausible financing. Fern\u00e1ndez commented on the value of Farmaindustria\u2019s initiative in having helped produced a complete and updated map of Spanish biomedical research, as well as best identifying sectors (both academia and biotech), and structuring their offer in line with appropriate priorities and criteria.<\/p>\n<p style=\"text-align: justify\">Antonio G\u00f3mez, business liaison of the Janssen Cilag Research Centers, explained how the biggest limitation affecting medicine development between basic and applied science is called the \u2018Valley of the dead\u2019, since \u201cthe projects that stem from academia have not the required degree of maturity that industry demands\u201d, so they need the latter to gain the technical and financial support to reach said maturity\u201d. According to G\u00f3mez, the\u00a0 Farma-Biotech facilitates walking through said Valley with the application of the appropriate selection criteria, increasing the guarantees of de-risking. Taking all actions needed in order to carry out a less risky project or one less likely to unleash an economic loss.<\/p>\n<p><img loading=\"lazy\" decoding=\"async\" class=\"size-medium wp-image-2950 aligncenter\" src=\"https:\/\/www.farmaindustria.es\/web_en\/wp-content\/uploads\/sites\/3\/2016\/10\/pharma-biotech-01-300x200.jpg\" alt=\"Farma-Biotech program- Farmaindustria\" width=\"300\" height=\"200\" srcset=\"https:\/\/www.farmaindustria.es\/web_en\/wp-content\/uploads\/sites\/3\/2016\/10\/pharma-biotech-01-300x200.jpg 300w, https:\/\/www.farmaindustria.es\/web_en\/wp-content\/uploads\/sites\/3\/2016\/10\/pharma-biotech-01-768x512.jpg 768w, https:\/\/www.farmaindustria.es\/web_en\/wp-content\/uploads\/sites\/3\/2016\/10\/pharma-biotech-01-1024x683.jpg 1024w, https:\/\/www.farmaindustria.es\/web_en\/wp-content\/uploads\/sites\/3\/2016\/10\/pharma-biotech-01-852x568.jpg 852w, https:\/\/www.farmaindustria.es\/web_en\/wp-content\/uploads\/sites\/3\/2016\/10\/pharma-biotech-01-50x33.jpg 50w\" sizes=\"auto, (max-width: 300px) 100vw, 300px\" \/><\/p>\n","protected":false},"excerpt":{"rendered":"<p>Bilbao, September 30th 2016.- Small biotech companies and start-ups, R&amp;D centers and pharmaceutical companies have highlighted the benefits that the Farma-Biotech program has generated for their activities. The Program was set up five years ago by Farmaindustria, and a summary of its recent activities was presented today in Bilbao in the context of the Biospain  <a href=\"https:\/\/www.farmaindustria.es\/web_en\/documents\/press-releases\/2016\/10\/04\/innovation-product-type-industrial-protection-keys-success-farma-biotechs-programme\/\" class=\"read-more\">&hellip;<\/a><\/p>\n","protected":false},"author":4,"featured_media":0,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"footnotes":""},"class_list":["post-2949","post","type-post","status-publish","format-standard","hentry","tema-pharma-biotech","tema-laboratorios","tema-investigacion-y-desarrollo","organismo-consejeria-de-sanidad-del-pais-vasco"],"acf":[],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.9 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Innovation, product type and industrial protection \u2013 the keys to the success of Farma-Biotech\u2019s programme - FarmaIndustria<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.farmaindustria.es\/web_en\/documents\/press-releases\/2016\/10\/04\/innovation-product-type-industrial-protection-keys-success-farma-biotechs-programme\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Innovation, product type and industrial protection \u2013 the keys to the success of Farma-Biotech\u2019s programme - FarmaIndustria\" \/>\n<meta property=\"og:description\" content=\"Bilbao, September 30th 2016.- Small biotech companies and start-ups, R&amp;D centers and pharmaceutical companies have highlighted the benefits that the Farma-Biotech program has generated for their activities. The Program was set up five years ago by Farmaindustria, and a summary of its recent activities was presented today in Bilbao in the context of the Biospain &hellip;\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.farmaindustria.es\/web_en\/documents\/press-releases\/2016\/10\/04\/innovation-product-type-industrial-protection-keys-success-farma-biotechs-programme\/\" \/>\n<meta property=\"og:site_name\" content=\"FarmaIndustria\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/pages\/Farmaindustria\/730634013647836?ref=hl\" \/>\n<meta property=\"article:published_time\" content=\"2016-10-04T10:35:10+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2016-10-04T10:37:26+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.farmaindustria.es\/web_en\/wp-content\/uploads\/sites\/3\/2016\/10\/pharma-biotech-01-300x200.jpg\" \/>\n<meta name=\"author\" content=\"Nathalie Rooney\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:creator\" content=\"@FarmaIndustria\" \/>\n<meta name=\"twitter:site\" content=\"@FarmaIndustria\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Nathalie Rooney\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"4 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.farmaindustria.es\\\/web_en\\\/documents\\\/press-releases\\\/2016\\\/10\\\/04\\\/innovation-product-type-industrial-protection-keys-success-farma-biotechs-programme\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.farmaindustria.es\\\/web_en\\\/documents\\\/press-releases\\\/2016\\\/10\\\/04\\\/innovation-product-type-industrial-protection-keys-success-farma-biotechs-programme\\\/\"},\"author\":{\"name\":\"Nathalie Rooney\",\"@id\":\"https:\\\/\\\/www.farmaindustria.es\\\/web_en\\\/#\\\/schema\\\/person\\\/0d4299f2aea1d36b54db40fc10230603\"},\"headline\":\"Innovation, product type and industrial protection \u2013 the keys to the success of Farma-Biotech\u2019s programme\",\"datePublished\":\"2016-10-04T10:35:10+00:00\",\"dateModified\":\"2016-10-04T10:37:26+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.farmaindustria.es\\\/web_en\\\/documents\\\/press-releases\\\/2016\\\/10\\\/04\\\/innovation-product-type-industrial-protection-keys-success-farma-biotechs-programme\\\/\"},\"wordCount\":759,\"commentCount\":0,\"image\":{\"@id\":\"https:\\\/\\\/www.farmaindustria.es\\\/web_en\\\/documents\\\/press-releases\\\/2016\\\/10\\\/04\\\/innovation-product-type-industrial-protection-keys-success-farma-biotechs-programme\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.farmaindustria.es\\\/web_en\\\/wp-content\\\/uploads\\\/sites\\\/3\\\/2016\\\/10\\\/pharma-biotech-01-300x200.jpg\",\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/www.farmaindustria.es\\\/web_en\\\/documents\\\/press-releases\\\/2016\\\/10\\\/04\\\/innovation-product-type-industrial-protection-keys-success-farma-biotechs-programme\\\/#respond\"]}]},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.farmaindustria.es\\\/web_en\\\/documents\\\/press-releases\\\/2016\\\/10\\\/04\\\/innovation-product-type-industrial-protection-keys-success-farma-biotechs-programme\\\/\",\"url\":\"https:\\\/\\\/www.farmaindustria.es\\\/web_en\\\/documents\\\/press-releases\\\/2016\\\/10\\\/04\\\/innovation-product-type-industrial-protection-keys-success-farma-biotechs-programme\\\/\",\"name\":\"Innovation, product type and industrial protection \u2013 the keys to the success of Farma-Biotech\u2019s programme - FarmaIndustria\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.farmaindustria.es\\\/web_en\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.farmaindustria.es\\\/web_en\\\/documents\\\/press-releases\\\/2016\\\/10\\\/04\\\/innovation-product-type-industrial-protection-keys-success-farma-biotechs-programme\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.farmaindustria.es\\\/web_en\\\/documents\\\/press-releases\\\/2016\\\/10\\\/04\\\/innovation-product-type-industrial-protection-keys-success-farma-biotechs-programme\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.farmaindustria.es\\\/web_en\\\/wp-content\\\/uploads\\\/sites\\\/3\\\/2016\\\/10\\\/pharma-biotech-01-300x200.jpg\",\"datePublished\":\"2016-10-04T10:35:10+00:00\",\"dateModified\":\"2016-10-04T10:37:26+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.farmaindustria.es\\\/web_en\\\/#\\\/schema\\\/person\\\/0d4299f2aea1d36b54db40fc10230603\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.farmaindustria.es\\\/web_en\\\/documents\\\/press-releases\\\/2016\\\/10\\\/04\\\/innovation-product-type-industrial-protection-keys-success-farma-biotechs-programme\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.farmaindustria.es\\\/web_en\\\/documents\\\/press-releases\\\/2016\\\/10\\\/04\\\/innovation-product-type-industrial-protection-keys-success-farma-biotechs-programme\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.farmaindustria.es\\\/web_en\\\/documents\\\/press-releases\\\/2016\\\/10\\\/04\\\/innovation-product-type-industrial-protection-keys-success-farma-biotechs-programme\\\/#primaryimage\",\"url\":\"https:\\\/\\\/www.farmaindustria.es\\\/web_en\\\/wp-content\\\/uploads\\\/sites\\\/3\\\/2016\\\/10\\\/pharma-biotech-01.jpg\",\"contentUrl\":\"https:\\\/\\\/www.farmaindustria.es\\\/web_en\\\/wp-content\\\/uploads\\\/sites\\\/3\\\/2016\\\/10\\\/pharma-biotech-01.jpg\",\"width\":2480,\"height\":1654,\"caption\":\"Farma-Biotech program- Farmaindustria\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.farmaindustria.es\\\/web_en\\\/documents\\\/press-releases\\\/2016\\\/10\\\/04\\\/innovation-product-type-industrial-protection-keys-success-farma-biotechs-programme\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.farmaindustria.es\\\/web_en\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Innovation, product type and industrial protection \u2013 the keys to the success of Farma-Biotech\u2019s programme\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.farmaindustria.es\\\/web_en\\\/#website\",\"url\":\"https:\\\/\\\/www.farmaindustria.es\\\/web_en\\\/\",\"name\":\"FarmaIndustria\",\"description\":\"\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.farmaindustria.es\\\/web_en\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.farmaindustria.es\\\/web_en\\\/#\\\/schema\\\/person\\\/0d4299f2aea1d36b54db40fc10230603\",\"name\":\"Nathalie Rooney\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a544889d96ab667147c2dddf3cdd9b4cdf2a0044511df45b193d666e09d8b3db?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a544889d96ab667147c2dddf3cdd9b4cdf2a0044511df45b193d666e09d8b3db?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a544889d96ab667147c2dddf3cdd9b4cdf2a0044511df45b193d666e09d8b3db?s=96&d=mm&r=g\",\"caption\":\"Nathalie Rooney\"},\"url\":\"https:\\\/\\\/www.farmaindustria.es\\\/web_en\\\/documents\\\/press-releases\\\/author\\\/franfranco\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Innovation, product type and industrial protection \u2013 the keys to the success of Farma-Biotech\u2019s programme - FarmaIndustria","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.farmaindustria.es\/web_en\/documents\/press-releases\/2016\/10\/04\/innovation-product-type-industrial-protection-keys-success-farma-biotechs-programme\/","og_locale":"en_US","og_type":"article","og_title":"Innovation, product type and industrial protection \u2013 the keys to the success of Farma-Biotech\u2019s programme - FarmaIndustria","og_description":"Bilbao, September 30th 2016.- Small biotech companies and start-ups, R&amp;D centers and pharmaceutical companies have highlighted the benefits that the Farma-Biotech program has generated for their activities. The Program was set up five years ago by Farmaindustria, and a summary of its recent activities was presented today in Bilbao in the context of the Biospain &hellip;","og_url":"https:\/\/www.farmaindustria.es\/web_en\/documents\/press-releases\/2016\/10\/04\/innovation-product-type-industrial-protection-keys-success-farma-biotechs-programme\/","og_site_name":"FarmaIndustria","article_publisher":"https:\/\/www.facebook.com\/pages\/Farmaindustria\/730634013647836?ref=hl","article_published_time":"2016-10-04T10:35:10+00:00","article_modified_time":"2016-10-04T10:37:26+00:00","og_image":[{"url":"https:\/\/www.farmaindustria.es\/web_en\/wp-content\/uploads\/sites\/3\/2016\/10\/pharma-biotech-01-300x200.jpg","type":"","width":"","height":""}],"author":"Nathalie Rooney","twitter_card":"summary_large_image","twitter_creator":"@FarmaIndustria","twitter_site":"@FarmaIndustria","twitter_misc":{"Written by":"Nathalie Rooney","Est. reading time":"4 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.farmaindustria.es\/web_en\/documents\/press-releases\/2016\/10\/04\/innovation-product-type-industrial-protection-keys-success-farma-biotechs-programme\/#article","isPartOf":{"@id":"https:\/\/www.farmaindustria.es\/web_en\/documents\/press-releases\/2016\/10\/04\/innovation-product-type-industrial-protection-keys-success-farma-biotechs-programme\/"},"author":{"name":"Nathalie Rooney","@id":"https:\/\/www.farmaindustria.es\/web_en\/#\/schema\/person\/0d4299f2aea1d36b54db40fc10230603"},"headline":"Innovation, product type and industrial protection \u2013 the keys to the success of Farma-Biotech\u2019s programme","datePublished":"2016-10-04T10:35:10+00:00","dateModified":"2016-10-04T10:37:26+00:00","mainEntityOfPage":{"@id":"https:\/\/www.farmaindustria.es\/web_en\/documents\/press-releases\/2016\/10\/04\/innovation-product-type-industrial-protection-keys-success-farma-biotechs-programme\/"},"wordCount":759,"commentCount":0,"image":{"@id":"https:\/\/www.farmaindustria.es\/web_en\/documents\/press-releases\/2016\/10\/04\/innovation-product-type-industrial-protection-keys-success-farma-biotechs-programme\/#primaryimage"},"thumbnailUrl":"https:\/\/www.farmaindustria.es\/web_en\/wp-content\/uploads\/sites\/3\/2016\/10\/pharma-biotech-01-300x200.jpg","inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/www.farmaindustria.es\/web_en\/documents\/press-releases\/2016\/10\/04\/innovation-product-type-industrial-protection-keys-success-farma-biotechs-programme\/#respond"]}]},{"@type":"WebPage","@id":"https:\/\/www.farmaindustria.es\/web_en\/documents\/press-releases\/2016\/10\/04\/innovation-product-type-industrial-protection-keys-success-farma-biotechs-programme\/","url":"https:\/\/www.farmaindustria.es\/web_en\/documents\/press-releases\/2016\/10\/04\/innovation-product-type-industrial-protection-keys-success-farma-biotechs-programme\/","name":"Innovation, product type and industrial protection \u2013 the keys to the success of Farma-Biotech\u2019s programme - FarmaIndustria","isPartOf":{"@id":"https:\/\/www.farmaindustria.es\/web_en\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.farmaindustria.es\/web_en\/documents\/press-releases\/2016\/10\/04\/innovation-product-type-industrial-protection-keys-success-farma-biotechs-programme\/#primaryimage"},"image":{"@id":"https:\/\/www.farmaindustria.es\/web_en\/documents\/press-releases\/2016\/10\/04\/innovation-product-type-industrial-protection-keys-success-farma-biotechs-programme\/#primaryimage"},"thumbnailUrl":"https:\/\/www.farmaindustria.es\/web_en\/wp-content\/uploads\/sites\/3\/2016\/10\/pharma-biotech-01-300x200.jpg","datePublished":"2016-10-04T10:35:10+00:00","dateModified":"2016-10-04T10:37:26+00:00","author":{"@id":"https:\/\/www.farmaindustria.es\/web_en\/#\/schema\/person\/0d4299f2aea1d36b54db40fc10230603"},"breadcrumb":{"@id":"https:\/\/www.farmaindustria.es\/web_en\/documents\/press-releases\/2016\/10\/04\/innovation-product-type-industrial-protection-keys-success-farma-biotechs-programme\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.farmaindustria.es\/web_en\/documents\/press-releases\/2016\/10\/04\/innovation-product-type-industrial-protection-keys-success-farma-biotechs-programme\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.farmaindustria.es\/web_en\/documents\/press-releases\/2016\/10\/04\/innovation-product-type-industrial-protection-keys-success-farma-biotechs-programme\/#primaryimage","url":"https:\/\/www.farmaindustria.es\/web_en\/wp-content\/uploads\/sites\/3\/2016\/10\/pharma-biotech-01.jpg","contentUrl":"https:\/\/www.farmaindustria.es\/web_en\/wp-content\/uploads\/sites\/3\/2016\/10\/pharma-biotech-01.jpg","width":2480,"height":1654,"caption":"Farma-Biotech program- Farmaindustria"},{"@type":"BreadcrumbList","@id":"https:\/\/www.farmaindustria.es\/web_en\/documents\/press-releases\/2016\/10\/04\/innovation-product-type-industrial-protection-keys-success-farma-biotechs-programme\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.farmaindustria.es\/web_en\/"},{"@type":"ListItem","position":2,"name":"Innovation, product type and industrial protection \u2013 the keys to the success of Farma-Biotech\u2019s programme"}]},{"@type":"WebSite","@id":"https:\/\/www.farmaindustria.es\/web_en\/#website","url":"https:\/\/www.farmaindustria.es\/web_en\/","name":"FarmaIndustria","description":"","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.farmaindustria.es\/web_en\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.farmaindustria.es\/web_en\/#\/schema\/person\/0d4299f2aea1d36b54db40fc10230603","name":"Nathalie Rooney","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a544889d96ab667147c2dddf3cdd9b4cdf2a0044511df45b193d666e09d8b3db?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a544889d96ab667147c2dddf3cdd9b4cdf2a0044511df45b193d666e09d8b3db?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a544889d96ab667147c2dddf3cdd9b4cdf2a0044511df45b193d666e09d8b3db?s=96&d=mm&r=g","caption":"Nathalie Rooney"},"url":"https:\/\/www.farmaindustria.es\/web_en\/documents\/press-releases\/author\/franfranco\/"}]}},"_links":{"self":[{"href":"https:\/\/www.farmaindustria.es\/web_en\/wp-json\/wp\/v2\/posts\/2949","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.farmaindustria.es\/web_en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.farmaindustria.es\/web_en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.farmaindustria.es\/web_en\/wp-json\/wp\/v2\/users\/4"}],"replies":[{"embeddable":true,"href":"https:\/\/www.farmaindustria.es\/web_en\/wp-json\/wp\/v2\/comments?post=2949"}],"version-history":[{"count":2,"href":"https:\/\/www.farmaindustria.es\/web_en\/wp-json\/wp\/v2\/posts\/2949\/revisions"}],"predecessor-version":[{"id":2954,"href":"https:\/\/www.farmaindustria.es\/web_en\/wp-json\/wp\/v2\/posts\/2949\/revisions\/2954"}],"wp:attachment":[{"href":"https:\/\/www.farmaindustria.es\/web_en\/wp-json\/wp\/v2\/media?parent=2949"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}